Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649042 | 0.99 | HRH3 (0.52) | MEN1LMNAHTTKMT2AHRH3 | |
| SCHEMBL9057922 | 0.83 | LMNA (0.70) | MEN1LMNAHTTKMT2AHRH3 | |
| SCHEMBL6653124 | 0.80 | KDM4E (0.53) | HRH3MAOAMAOB | |
| SCHEMBL7821188 | 0.78 | HRH3 (0.53) | MEN1LMNAHTTKMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL8055682 | 0.77 | HRH3 (0.52) | MEN1LMNAHTTKMT2AHRH3 | |
| SCHEMBL6655573 | 0.77 | KMT2A (0.60) | MEN1LMNAKMT2AHRH3MAOA | |
| SCHEMBL3886790 | 0.77 | KDM4E (0.59) | HRH3ALDH1A1 | |
| SCHEMBL6652158 | 0.75 | HRH3 (0.51) | HRH3USP2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL6728490 | 0.74 | HRH3 (0.50) | HRH3USP2ALDH1A1HPGD | |
| SCHEMBL7816469 | 0.74 | HRH3 (0.57) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143971-B1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PF MEDICAMENT (FR) | 2004-06-02 | — | — | EP | disclosed |
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | PIERRE FABRE MEDICAMENT (FR) | 2004-01-22 | — | — | US | disclosed |
| US-6583159-B1 | Myocardial ischemia; cytoprotective properties | PIERRE FABRE MEDICAMENT (FR) | 2003-06-24 | — | — | US | disclosed |
| EP-1143971-A1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PIERRE FABRE MEDICAMENT (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043011-A1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PIERRE FABRE MEDICAMENT (FR) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | AQP1, SLCO2A1, SLCO2B1 | MEN1 1955/4885LMNA 3830/4885HTT 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.